AbbVie strikes $10.9B Apogee buy to challenge juggernaut Dupixent
AbbVie will add Apogee’s IL-23 blocker to its current immunology stalwarts Skyrizi and Rinvoq, which have helped the pharma ride out the steep patent cliff left behind from mega-blockbuster drug Humira.
Read the full article on the original site.
Read Full Article